DNA/RNA-based next-generation sequencing allows earlier diagnosis of neoplastic bile duct strictures, a prospective multicenter real-time study finds.

If you or a loved one has gallbladder or bile duct cancer, you may be interested in learning more about treatments for it. For a long time, the standard treatment options for this cancer type were ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated ...

The PATHWAY HER2 (4B5) test helps to identify patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA.

Biliary Tract Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the ...

Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...

Bile duct cancer is classified by location: intrahepatic, perihilar, or distal, influencing symptoms and treatment options. Diagnosis involves blood tests, imaging, endoscopic procedures, and biopsy ...

Cancer is a disease that can be treated more effectively if diagnosed early. However, some types of cancer have mild early symptoms and mimic common health problems. Therefore, the disease is often ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

Bile duct cancer, or cholangiocarcinoma, is a serious concern due to its rapid progression and often mild, easily mistaken ...

New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter second-line sequencing. In an interview with Targeted Oncology, Linda Y. Wu, MD, ...

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary ...